<SEC-DOCUMENT>0001213900-21-005980.txt : 20210202
<SEC-HEADER>0001213900-21-005980.hdr.sgml : 20210202
<ACCEPTANCE-DATETIME>20210202083038
ACCESSION NUMBER:		0001213900-21-005980
CONFORMED SUBMISSION TYPE:	POS EX
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20210202
DATE AS OF CHANGE:		20210202
EFFECTIVENESS DATE:		20210202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NLS Pharmaceutics Ltd.
		CENTRAL INDEX KEY:			0001783036
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POS EX
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-236797
		FILM NUMBER:		21579121

	BUSINESS ADDRESS:	
		STREET 1:		ALTER POSTPLATZ 2
		CITY:			STANS
		STATE:			V8
		ZIP:			CH-6370
		BUSINESS PHONE:		41-41-618-80-00

	MAIL ADDRESS:	
		STREET 1:		ALTER POSTPLATZ 2
		CITY:			STANS
		STATE:			V8
		ZIP:			CH-6370
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS EX
<SEQUENCE>1
<FILENAME>ea134192-posex_nlspharma.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
filed on February 2, 2021 with the Securities and Exchange Commission</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-236797</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES SECURITIES AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
DC 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>POST-EFFECTIVE
AMENDMENT NO. 1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form&nbsp;F-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>NLS
Pharmaceutics Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Exact
name of registrant as specified in its charter)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Switzerland</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Not&nbsp;Applicable</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(State&nbsp;or&nbsp;other&nbsp;jurisdiction&nbsp;of</I><BR>
    <I>incorporation&nbsp;or&nbsp;organization)</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Primary&nbsp;Standard&nbsp;Industrial</I><BR>
    <I>Classification&nbsp;Code&nbsp;Number)</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(I.R.S.&nbsp;Employer</I><BR>
    <I>Identification&nbsp;Number)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alexander
    Zwyer</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief
    Executive Officer</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Puglisi&nbsp;&amp;
    Associates</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alter
    Postplatz 2</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>850
    Library Ave., Suite&nbsp;204</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CH-6370
    Stans, Switzerland</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Newark,
    DE 19711</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel:
    +41.41.618.80.00</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel:
    (302) 738-6680</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Address,
    including zip code, and telephone number,</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Name,
    address, including zip code, and telephone</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>including
    area code, of registrant&rsquo;s principal executive offices)</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>number,
    including area code, of agent for service)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Copies
to:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Oded
    Har-Even, Esq.</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 24%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 24%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 24%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Howard
    Berkenblit, Esq.</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mitchell
    Nussbaum, Esq.&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hans-Jakob
    Diem, Esq.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ron
    Ben-Bassat, Esq.</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pascal
    Honold, Esq.</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Angela
    M. Dowd, Esq.&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;Patrick
    Schleiffer, Esq.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sullivan
    &amp; Worcester LLP</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Wenger
    &amp; Vieli AG</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Loeb
    &amp; Loeb LLP&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lenz
    &amp; Staehelin&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1633
    Broadway</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dufourstrasse
    56</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>345
    Park Ave.&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Brandschenkestrasse
    24&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
    York, NY 10019</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>Zurich,
    Switzerland CH-8034</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
    York, NY 10154&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Zurich,
    Switzerland CH-8027</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel:
    212.660.5000</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel:
    +41.58.958.58.58</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel:
    212.407.4000</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel:
    +41.58.450.8000</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approximate
date of commencement of proposed sale to the public:</B>&nbsp;As soon as practicable after the effective date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415
under the Securities Act, check the following box.&nbsp;&nbsp;&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, check
the following box and list the Securities Act registration statement number of the earlier effective registration statement for
the same offering.&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box
and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. &#9746; 333-236797</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company&nbsp;&nbsp;&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
&dagger; provided pursuant to Section 7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&dagger;The
term &ldquo;new or revised financial accounting standard&rdquo; refers to any update issued by the Financial Accounting Standards
Board to its Accounting Standards Codification after April 5, 2012.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXPLANATORY
NOTE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Post-Effective Amendment No. 1 (this &ldquo;Post-Effective Amendment&rdquo;) to the Registration Statement on Form F-1 (Registration
No. 333-236797) (the &ldquo;Registration Statement&rdquo;) is being filed pursuant to Rule 462(d) under the Securities Act of
1933, as amended (the &ldquo;Securities Act&rdquo;), solely to replace Exhibit 5.1 as indicated in Part II of this Post-Effective
Amendment. The Registration Statement was declared effective by the Securities and Exchange Commission on January 28, 2021. This
Post-Effective Amendment does not modify any provision of the preliminary prospectus constituting Part I the Registration Statement.
Accordingly, this Post-Effective Amendment consists only of the facing page, this explanatory note, Part II of the Registration
Statement, the signature page to this Post-Effective Amendment and Exhibit 5.1. This Post-Effective Amendment shall become effective
upon filing with the Commission in accordance with Rule 462(d) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;6.
Indemnification of Directors, Officers and Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Swiss law, a corporation may indemnify its directors or officers against losses and expenses (except for such losses and expenses
arising from willful misconduct or negligence, although legal scholars advocate that at least gross negligence be required; however,
some scholars also advocate that with any breach of duty, indemnification by the Company is not permissible), including attorney&rsquo;s
fees, judgments, fines and settlement amounts actually and reasonably incurred in a civil or criminal action, suit or proceeding
by reason of having been the representative of, or serving at the request of, the corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to Swiss law, our articles of association provide for indemnification of the existing and former members of our board of directors,
executive management, and their heirs, executors and administrators, against liabilities arising in connection with the performance
of their duties in such capacity, and permit us to advance the expenses of defending any act, suit or proceeding to members of
our board of directors and executive management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under general principles of Swiss employment law, an employer may be required to indemnify an employee against losses
and expenses incurred by such employee in the proper execution of his or her duties under the employment agreement with the company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to enter into indemnification agreements with each of the members of our board of directors and executive officers in the
form to be filed as an exhibit to this registration statement upon the completion of this offering. Irrespective of our entering
or not entering into indemnification agreements with our board of directors and executive officers, prior to or shortly after
the completion of this offering, we intend to take out directors&rsquo; and officers&rsquo; liability insurance&nbsp;to cover
certain actions undertaken by our board of directors and executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, may be permitted
to directors, officers and controlling persons of the Company, the Company has been advised that, in the opinion of the Securities
and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act, and is, therefore,
unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;7.
Recent Sales of Unregistered Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below are the sales of all securities by the Company since November 2017, which were not registered under the Securities
Act. The Company believes that each of such issuances was exempt from registration under the Securities Act in reliance on Section
4(a)(2) of the Securities Act, Rule 701 and/or Regulation S under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 14, 2020, our shareholders approved an amendment to our articles of association, which reflects a 5,000 for 1 stock
split of our common shares, effective as of&nbsp;September 14, 2020, or the Share Split. Information in this Item 7 reflects the
Share Split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 17, 2018, we issued an aggregate of 260,000 of our common shares to the Shareholders, in connection with the conversion of
an aggregate amount of $3,418,519 borrowed by us pursuant to a $7.1 million credit facility, or the Credit Facility, at a conversion
price of $13 per common share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 12, 2019, we issued an aggregate of 280,000 of our common shares to the Shareholders, in connection with the conversion
of the remaining $3,681,481 borrowed by us pursuant to the Credit Facility, at a conversion price of $13 per common share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
on March 12, 2019, we issued an aggregate of an additional 40,000 of our common shares to Magnetic Rock Investment AG in connection
with the conversion CHF 526,979.84 ($526,769) of a CHF 550,000 ($557,920) convertible promissory note at a conversion price of
CHF 13 (approximately $13) per common share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 12, 2019, there was a reorganization of our Company, whereby NLS-0 Pharma AG and NLS Pharma AG merged into the Company,
or the Merger, and as a result thereof, and in connection therewith, we issued and subsequently assigned an aggregate of 745,000
of our common shares to those holders of NLS-0 and NLS Pharma common shares, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 12, 2019, simultaneously with the closing of the Merger, we issued an aggregate of 260,000 of our common shares to the Shareholders,
in exchange for the consideration of the conversion of a bridge loan in the amount of $2 million and a credit facility, of which
we had drawn $1.45 million, at a conversion price of $13 per common share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;8.
Exhibits and Financial Statement Schedules</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibits:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    Number</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 90%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390021002942/ea133431ex1-1_nlspharma.htm">Form of Underwriting Agreement by and among NLS Pharmaceutics Ltd. and the underwriters named therein.</A></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020031906/ea128281ex3-1_nlspharma.htm">Form of Amended and Restated Articles of Association of NLS Pharmaceutics Ltd.</A></FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020036675/ea129645ex1-1_nlspharma.htm">Form of Representative&rsquo;s Warrant (included in Exhibit 1.1)</A></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020036675/ea129645ex4-2_nlspharma.htm">Form of Warrant Agent Agreement.</A></FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020036675/ea129645ex4-3_nlspharma.htm">Form of Warrant.</A></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="ea134192ex5-1_nlspharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Wenger &amp; Vieli AG, Swiss counsel to NLS Pharmaceutics Ltd.</FONT></A></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020036675/ea129645ex5-2_nlspharma.htm">Opinion of Sullivan &amp; Worcester LLP, U.S. counsel to NLS Pharmaceutics Ltd.</A></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020005070/ea119052ex10-1_nlspharma.htm">Merger Agreement dated March 12, 2019 between NLS-1 Pharma AG, NLS-0 Pharma AG and NLS Pharma AG.</A></FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020005070/ea119052ex10-2_nlspharma.htm">Convertible Promissory Note dated January 18, 2019 between Magnetic Rock Investment AG and the Company.</A></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020005070/ea119052ex10-3_nlspharma.htm">Addendum to Convertible Promissory Note dated January 18, 2019 between Magnetic Rock Investment AG and the Company.</A></FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020005070/ea119052ex10-4_nlspharma.htm">Addendum Number 2 to Convertible Promissory Note dated January 18, 2019 between Magnetic Rock Investment AG and the Company.</A></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020005070/ea119052ex10-5_nlspharma.htm">Form of Promissory Note dated January 2019 between certain investors and the Company.</A></FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020005070/ea119052ex10-6_nlspharma.htm">Form of Addendum to Promissory Note dated January 2019 between certain investors and the Company.</A></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020005070/ea119052ex10-7_nlspharma.htm">Form of Addendum Number 2 to Promissory Note dated January 2019 between certain investors and the Company.</A></FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020005070/ea119052ex10-8_nlspharma.htm">Credit Facility dated August 31, 2015 between NLS Pharma AG and the Lenders named therein.</A></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020005070/ea119052ex10-9_nlspharma.htm">Addendum to Credit Facility dated August 31, 2015 between NLS Pharma AG and the Lenders named therein.</A></FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020005070/ea119052ex10-10_nlspharma.htm">Addendum Number 2 to Credit Facility dated August 31, 2015 between NLS Pharma AG and the Lenders named therein.</A></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020005070/ea119052ex10-11_nlspharma.htm">Credit Facility dated August 31, 2015 between NLS-1 Pharma AG and the Lenders named therein.</A></FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020005070/ea119052ex10-12_nlspharma.htm">Addendum Number 1 to Credit Facility dated August 31, 2015 between NLS-1 Pharma AG and the Lenders named therein.</A></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020005070/ea119052ex10-13_nlspharma.htm">Addendum Number 2 to Credit Facility dated August 31, 2015 between NLS-1 Pharma AG and the Lenders named therein.</A></FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020005070/ea119052ex10-14_nlspharma.htm">License Agreement dated February 2019 between Eurofarma Laboratorios S.A. and the Company.</A></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020005070/ea119052ex10-15_nlspharma.htm">Assignment and Transfer Agreement dated August 31, 2015 between NLS-1 AG and NeuroLife Sciences SAS.</A></FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020005070/ea119052ex10-16_nlspharma.htm">First Amendment to Assignment and Transfer Agreement dated August 31, 2015 between NLS-1 AG and NeuroLife Sciences SAS.</A></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020005070/ea119052ex10-17_nlspharma.htm">Second Amendment to Assignment and Transfer Agreement dated August 31, 2015 between NLS-1 AG and NeuroLife Sciences SAS.</A></FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020005070/ea119052ex10-18_nlspharma.htm">Form of Convertible Loan Agreement between NLS Pharmaceutics Ltd. and certain lenders.</A></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19^</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020024460/ea125945ex10-19_nlspharma.htm">Amendment Number 1 to Convertible Loan Agreement dated February 21, 2020 between NLS Pharmaceutics Ltd. and Alexander Zwyer.</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020031906/ea128281ex10-20_nlspharma.htm">Amendment Number 2 to Convertible Loan Agreement dated February 21, 2020 between NLS Pharmaceutics Ltd. and Alexander Zwyer.</A></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020031906/ea128281ex10-21_nlspharma.htm">Amendment Number 3 to Convertible Loan Agreement dated February 21, 2020 between NLS Pharmaceutics Ltd. and Alexander Zwyer.</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020031906/ea128281ex10-22_nlspharma.htm">Bridge Loan Agreement between NLS Pharmaceutics Ltd. and Magnetic Rock Investment AG.</A></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020031906/ea128281ex10-23_nlspharma.htm">Amendment to Bridge Loan Agreement between NLS Pharmaceutics Ltd. and Magnetic Rock Investment AG.</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020031906/ea128281ex10-24_nlspharma.htm">Form of Amendment to Convertible Loan Agreement between NLS Pharmaceutics Ltd. and certain lenders.</A></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020031906/ea128281ex10-25_nlspharma.htm">Form of Addendum Number 3 to Promissory Note dated January 2019 between certain investors and the Company.</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020031906/ea128281ex10-26_nlspharma.htm">Addendum Number 3 to Credit Facility dated August 31, 2015 between NLS Pharma AG and the Lenders named therein.</A></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020031906/ea128281ex10-27_nlspharma.htm">Addendum Number 3 to Credit Facility dated August 31, 2015 between NLS-1 Pharma AG and the Lenders named therein.</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020031906/ea128281ex10-28_nlspharma.htm">Addendum Number 3 to Convertible Promissory Note dated January 18, 2019 between Magnetic Rock Investment AG and the Company.</A></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390021002942/ea133431ex10-29_nlspharma.htm">Amendment Number 4 to Convertible Loan Agreement dated February 21, 2020 between NLS Pharmaceutics Ltd. and Alexander Zwyer.</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390021002942/ea133431ex10-30_nlspharma.htm">Amendment Number 2 to Bridge Loan Agreement between NLS Pharmaceutics Ltd. and Magnetic Rock Investment AG.</A></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390021002942/ea133431ex10-31_nlspharma.htm">Amendment Number 3 to Bridge Loan Agreement between NLS Pharmaceutics Ltd. and Magnetic Rock Investment AG.</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390021002942/ea133431ex10-32_nlspharma.htm">Form of Addendum Number 4 to Promissory Note dated January 2019 between certain investors and the Company.</A></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390021002942/ea133431ex10-33_nlspharma.htm">Addendum Number 4 to Credit Facility dated August 31, 2015 between NLS Pharma AG and the Lenders named therein.</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390021002942/ea133431ex10-34_nlspharma.htm">Addendum Number 4 to Credit Facility dated August 31, 2015 between NLS-1 Pharma AG and the Lenders named therein.</A></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390021002942/ea133431ex10-35_nlspharma.htm">Addendum Number 4 to Convertible Promissory Note dated January 18, 2019 between Magnetic Rock Investment AG and the Company.</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390021002942/ea133431ex23-1_nlspharma.htm">Consent of Marcum LLP.</A></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="ea134192ex5-1_nlspharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Wenger &amp; Vieli AG, Swiss counsel to NLS Pharmaceutics Ltd. (included in Exhibit 5.1).</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020036675/ea129645ex5-2_nlspharma.htm">Consent of Sullivan &amp; Worcester LLP, U.S. counsel to NLS Pharmaceutics Ltd. (included in Exhibit 5.2).</A></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390021002942/ea133431-f1a5_nlspharma.htm#b1">Power of Attorney (included on the signature page of the Registration Statement).</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020031906/ea128281ex99-1_nlspharma.htm">Consent of Stig L&oslash;kke Pedersen.</A></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390020031906/ea128281ex99-2_nlspharma.htm">Consent of Myoung-Ok Kwon.</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3^</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390021002942/ea133431ex99-3_nlspharma.htm">Registrant&rsquo;s Representation Pursuant to Requirements of Form 20-F, Item 8.A.4.</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">^</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously filed.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
Statement Schedules:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
financial statement schedules have been omitted because either they are not required, are not applicable or the information required
therein is otherwise set forth in the Company&rsquo;s financial statements and related notes thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;9.
Undertakings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and
controlling persons of the registrant pursuant to the provisions described in Item&nbsp;6 hereof, or otherwise, the registrant
has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the
registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense
of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed
in the Act and will be governed by the final adjudication of such issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The undersigned registrant hereby undertakes that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
That for purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus
filed as part of this registration statement in reliance upon Rule&nbsp;430A and contained in a form of prospectus filed by the
registrant pursuant to Rule&nbsp;424(b)(1) or (4), or 497(h) under the Securities Act shall be deemed to be part of this registration
statement as of the time it was declared effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
That for the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains
a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering
of such securities at that time shall be deemed to be the initial&nbsp;<I>bona fide</I>&nbsp;offering thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of&nbsp;1933, the registrant certifies that it has reasonable grounds to believe that
it meets all of the requirements for filing on Form F-1 and has duly caused this registration statement on Form F-1 to be signed
on its behalf by the undersigned, thereunto duly authorized, in&nbsp;Stans, Switzerland on February 2, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NLS Pharmaceutics Ltd.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Alexander Zwyer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander Zwyer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned officers and directors of
NLS Pharmaceutics Ltd. hereby constitute and appoint each of Alexander Zwyer and Robert Dickey with full power of substitution,
each of them singly our true and lawful attorneys-in-fact and agents to take any actions to enable the Company to comply with the
Securities Act, and any rules, regulations and requirements of the SEC, in connection with this amendment to the registration statement
on Form F-1, including the power and authority to sign for us in our names in the capacities indicated below any and all further
amendments to this registration statement and any other registration statement filed pursuant to the provisions of Rule 462 under
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, this registration statement on Form F-1 has been signed by the following persons
in the capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 41%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 31%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Alexander Zwyer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 2, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander Zwyer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Robert Dickey</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 2, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert Dickey</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ronald Hafner</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 2, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald Hafner</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Pascal Brenneisen</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 2, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pascal Brenneisen</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Myoung-Ok Kwon, Ph.D.</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 2, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Myoung-Ok Kwon, Ph.D.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Stig L&oslash;kke Pedersen</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 2, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stig L&oslash;kke Pedersen</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURE
OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Act of 1933, as amended, the undersigned,&nbsp;Puglisi &amp; Associates, the duly authorized representative
in the United States of&nbsp;NLS Pharmaceutics Ltd., has signed this registration statement on&nbsp;February 2, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Puglisi &amp; Associates</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Donald J. Puglisi</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald J. Puglisi</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing Director</FONT></TD></TR>
</TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ea134192ex5-1_nlspharma.htm
<DESCRIPTION>OPINION OF WENGER & VIELI AG, SWISS COUNSEL TO NLS PHARMACEUTICS LTD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0pt; text-align: right">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><IMG SRC="ex5-1_001.jpg" ALT=""></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 74%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NLS
Pharmaceutics Ltd</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alter
Postplatz 2</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6370
Stans</FONT></P>
        <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Switzerland</FONT></P>
        <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Z&uuml;rich,
        2 February 2021</FONT></P>
        <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NLS
        Pharmaceutics Ltd &ndash; Registration Statement on Form F-1</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Ladies
        and Gentlemen,</FONT></P>
        <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
        have acted as special Swiss counsel to NLS Pharmaceutics Ltd, a stock corporation incorporated under the laws of Switzerland
        (the &ldquo;<B>Company</B>&rdquo;), in connection with the filing of a Registration Statement (as defined below), including
        the prospectus set forth therein, with the United States Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;)
        for the purpose of registering under the United States Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;),
        the offer and sale of up to (i) 4,819,277 common shares (the &ldquo;<B>Common Shares</B>&rdquo;), par value CHF 0.02 per
        share (the &ldquo;<B>Firm Shares</B>&rdquo;), (ii) warrants (the &ldquo;<B>Common Warrants</B>&rdquo;) to purchase up to additional
        4,819,277 Common Shares, (iii) at the option of the several underwriters (the &ldquo;<B>Underwriters</B>&rdquo;), the issuance
        and sale to the Underwriters of up to additional 722,891 Common Shares (the &ldquo;<B>Overallotment Shares</B>&rdquo; and
        together with the Firm Shares, the &ldquo;<B>Shares</B>&rdquo;) and/or Common Warrants to purchase up to additional 722,891
        Common Shares (the &ldquo;<B>Overallotment Warrants</B>&rdquo; and together with the Common Warrants, the &ldquo;<B>Warrants</B>&rdquo;),
        and (iv) warrants (the &ldquo;<B>Underwriter Warrants</B>&rdquo;) to purchase additional Common Shares issued to the Underwriters
        (Common Shares for which Warrants and Underwriter Warrants are granted, the &ldquo;<B>Warrant Shares</B>&rdquo;). As such
        counsel, we have been requested to give our opinion as to certain legal matters of Swiss law.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Capitalized
        terms used but not defined herein shall have the meaning ascribed to them in the Documents (as defined below).</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.&#9;Christoph
                                         Schmid&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.&#9;Peter
        Altorfer&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Bignia
        Vieli <SUB>LL.M.&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.&#9;Michael
        Huber <SUB>LL.M.</SUB>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Georg
        Zondler&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.&#9;Wolfgang
        Z&uuml;rcher <SUB>LL.M.</SUB> <SUP>3, 4</SUP>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.&#9;Christian
        Wenger <SUB>LL.M.&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.&#9;Andreas
        H&uuml;nerwadel <SUB>LL.M.&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.&#9;Urs
        Weber-Stecher <SUB>LL.M.&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.&#9;Frank
        Scherrer <SUB>LL.M.&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.&#9;Beat
        Walti&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.&#9;Roman
        Heiz <SUB>LL.M.&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.&#9;Michael
        Mr&aacute;z&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Barbara
        Brauchli Rohrer <SUP>1, 2</SUP>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.&#9;Beat
        D. Speck <SUB>LL.M.</SUB> <SUP>3, 4</SUP>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Bruno
        B&auml;chli <SUP>1, 2</SUP>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Pascal
        Honold <SUB>LL.M.&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Philipp
        C. Lindenmayer <SUB>LL.M.&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.&#9;Nicolas
        Bracher <SUB>LL.M.&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dominik
        B&uuml;rgy <SUP>1, 2</SUP>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.&#9;Michael
        Tschudin&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Stefan
        M&uuml;ller <SUB>LL.M.</SUB> <SUP>3, 4</SUP>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Regula
        Grunder <SUB>LL.M.&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Claudia
        Keller <SUB>LL.M.&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Flavio
        Peter <SUB>LL.M.&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Marc
        Gerber <SUP>1</SUP>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Daniel
        S. Weber <SUB>LL.M.&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.&#9;Martin
        Peyer <SUB>LL.M.&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Patrick
        N&auml;f <SUB>LL.M.&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Marc
        Walter <SUB>LL.M.&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.&#9;Michael
        Baier <SUB>LL.M.</SUB> <SUP>3, 4</SUP>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Bastian
        Thurneysen <SUB>LL.M.</SUB> <SUP>1</SUP>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.&#9;Daniel
        P. Oehri <SUB>LL.M.</SUB> <SUP>4</SUP>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Martin
        Berweger <SUP>3, 4</SUP>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Florian
        Wegmann&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Stephanie
        Lienhard&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Ursina
        B&ouml;ni <SUP>2</SUP>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Sebastian
        Huber <SUB>LL.M.&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Mich&egrave;le
        Joho <SUP>3, 4</SUP>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.&#9;Andrea
        Sch&uuml;tz <SUB>LL.M.&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.&#9;Marcel
        Boller&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Markus
        Seglias <SUP>1, 2</SUP>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Mike
        Abegg <SUB>LL.M.&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Sabine
        Taxer <SUP>4</SUP>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Lilith
        Ritzmann&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Meltem
        Steudler&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Alessa
        Waibel <SUB>LL.M.&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Nadine
        Zanetti&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Deborah
        Sutter&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Patric
        Eggler <SUP>1, 2</SUP>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dominique
        Roos&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Nathalie
        Germann <SUP>4</SUP>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dominik
        Rietiker <SUP>3, 4</SUP>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Michelle
        Wiki&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dominique
        Mattmann&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">No&euml;mi
        Kunz-Schenk <SUP>1, 2</SUP>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">David
        Wohlgemuth&nbsp;&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.Marco
        Cereghetti <SUB>Konsulent</SUB>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Prof.
        Dr.Lorenz Droese <SUB>Konsulent</SUB>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Prof.
        Dr.Daniel Girsberger <SUB>LL.M. Konsulent&nbsp;</SUB></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">Dr.Urs
        Landolf <SUB>Konsulent</SUB> <SUP>2</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt"><IMG SRC="ex5-1_002.jpg" ALT="">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="padding: 0; width: 24%; text-align: left; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><SUP>1</SUP>Dipl.
    Steuerexperte / Steuerexpertin</FONT></TD>
    <TD STYLE="padding: 0; width: 24%; text-align: left; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><SUP>2</SUP>Nicht
    als Anwalt / Anw&auml;ltin zugelassen</FONT></TD>
    <TD STYLE="padding: 0; width: 24%; text-align: left; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><SUP>3</SUP>Notar
    / Notarin des Kantons Zug</FONT></TD>
    <TD STYLE="padding: 0; width: 28%; text-align: left; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><SUP>4</SUP>Eingetragen
    im Anwaltsregister des Kantons Zug</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>I.</B></FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Basis
                                         of Opinion</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
opinion is confined to and given on the basis of the laws of Switzerland in force at the date hereof. Such laws and the interpretation
thereof are subject to change. In the absence of explicit statutory law, we base our opinion solely on our independent professional
judgment. This opinion is also confined to the matters stated herein and is not to be read as extending, by implication or otherwise,
to any other matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
purposes of this opinion we have not conducted any due diligence or similar investigation as to factual circumstances, which are
or may be referred to in the Documents (as defined hereafter), and we express no opinion as to the accuracy of representations
and warranties of facts set out in the Documents or the factual background assumed therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
purposes of this opinion, we have only reviewed originals or copies of the following documents we have deemed necessary or advisable
for the purpose of rendering this opinion (collectively the &ldquo;<B>Documents</B>&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">An
                                         electronic copy of the registration statement on Form F-1 (Registration No. 333-236797)
                                         filed by the Company to the SEC (as amended to date, the &ldquo;<B>Registration Statement</B>&rdquo;);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">an
                                         electronic copy of the articles of association (<I>Statuten</I>) of the Company dated
                                         29 January 2021 (the &ldquo;<B>Articles</B>&rdquo;), as filed with the Commercial Register
                                         of the Canton of Nidwalden;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">an
                                         electronic copy of the excerpt of the electronic publication in the SHAB (Swiss Official
                                         Gazette of Commerce) in respect of the Company dated 2 January 2021 (the &ldquo;<B>Excerpt</B>&rdquo;);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">an
                                         electronic copy of the notarized shareholders&rsquo; resolutions passed at the Company&rsquo;s
                                         extraordinary general meeting held on 29 January 2021, resolving on (i) an ordinary capital
                                         increase for the creation of the Firm Shares, and (ii) certain amendments to the Articles
                                         with respect to the authorized share capital for the Overallotment Shares and the conditional
                                         share capital as underlying for the Warrants and Underwriter Warrants (the &ldquo;<B>Shareholders&rsquo;
                                         Resolutions</B>&rdquo;); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">an
                                         electronic copy of the notarized resolutions of the Company&rsquo;s board of directors dated
                                         29 January 2021 regarding the implementation of the ordinary capital increase (<I>Feststellungsbeschluss</I>)
                                         and the corresponding amendments to the Articles (the &ldquo;<B>Board Resolutions</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">No
documents, other than the Documents, have been reviewed by us in connection with this opinion. Accordingly, we shall limit our
opinion to the Documents and their legal implications under Swiss law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>II.</B></FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Assumptions</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
rendering the opinion below, we assumed:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         genuineness of all signatures;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         completeness of and conformity to the originals of all Documents submitted to us as copies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">that
                                         the Registration Statement has been duly filed by the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">that
                                         the Registration Statement is effective and will continue to be effective and the offering
                                         and sale of and payment for the Shares and Warrant Shares will be in accordance with
                                         the limitations referred to in the Registration Statement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">to
                                         the extent relevant for purposes of this opinion, that all factual information contained
                                         in, or material statements given in connection with, the Documents are true, complete
                                         and accurate;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">no
                                         laws (other than those of Switzerland) affect any of the conclusions stated in this opinion;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">g)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">prior
                                         to the issuance of any Firm Shares, the existing shareholders will have voluntarily waived
                                         their pre-emptive rights regarding the Firm Shares;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">h)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">prior
                                         to the issuance of any Overallotment Shares, (i) the board of directors of the Company
                                         will have duly authorized the issuance and sale of such Overallotment Shares (in particular
                                         a resolution of the Company&rsquo;s board of directors regarding the implementation of the
                                         authorized capital increase <I>(Feststellungsbeschluss)</I> was made) and such authorization
                                         will not have been amended and will be in full force and effect until the issuance of
                                         all Overallotment Shares, (ii) the Overallotment Shares are fully paid-in as to their
                                         nominal value on a bank account of a Swiss licensed bank in Switzerland and (iii) the
                                         board of directors of the Company will have validly excluded the pre-emptive rights of
                                         the existing shareholders for purposes of offering and selling the Overallotment Shares;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">prior
                                         to the issuance of any Warrant Shares (i) the exercise notice to exercise the respective
                                         Warrants and Underwriter Warrants will have been properly delivered to the Company, (ii)
                                         such Warrant Shares will be fully paid-in on a bank account of a Swiss licensed bank
                                         in Switzerland as to their exercise price of at least nominal value, and (iii) the board
                                         of directors of the Company will have validly excluded the pre-emptive rights of the
                                         existing shareholders for purposes of offering and selling the Warrant Shares;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">j)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         Overallotment Shares and Warrant Shares are issued and delivered in accordance with the
                                         Registration Statement (including, for the avoidance of doubt, any annexes filed as exhibits
                                         to the Registration Statement); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">k)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">all
                                         authorizations, approvals, consents, licenses, exemptions, other than as required by
                                         mandatory Swiss law applicable to the Company or the Articles, and other requirements
                                         for the filing of the Registration Statement or for any other activities carried on in
                                         view of, or in connection with, the performance of the obligations expressed to be undertaken
                                         by the Company in the Registration Statement have been duly obtained or fulfilled in
                                         due time and are and will remain in full force and effect, and any related conditions
                                         to which the parties thereto are subject have been satisfied.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>III.</B></FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Opinion</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based
upon the foregoing and subject to the qualifications set out below, we are of the opinion that the Shares and the Warrant Shares
issuable upon the proper exercise of the Warrants and Underwriter Warrants, when sold and upon registration of the corresponding
share capital increase into the Commercial Register of the Canton of Nidwalden, will be validly issued, fully paid-in (up to their
nominal amount) and non-assessable (which term means when used herein that no further contributions have to be made by the holders
of the Shares and the Warrant Shares).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>IV.</B></FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Qualifications
                                         </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
opinion is subject to the following qualifications:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
                                         opinion is limited to matters of Swiss law as in force on the date hereof and as applied
                                         and construed by the courts of Switzerland.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
                                         express no opinion as to any commercial, calculating, auditing or other non-legal matters.
                                         Further, this opinion does not cover any matter relating to Swiss or foreign taxes. This
                                         opinion is also confined to the matters stated herein and is not to be read as extending,
                                         by implication or otherwise, to any other matter.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
this opinion, Swiss legal concepts are expressed in English terms and not in their original Swiss language. The concepts concerned
may not be identical to the concepts described by the same English terms as they exist under the laws of other jurisdictions.
This opinion may, therefore, only be relied upon under the express condition that any issues of interpretation or liability arising
hereunder will be governed by Swiss law and that any dispute arising out of or in connection with this opinion shall be subject
to the exclusive jurisdiction of Zurich 1, Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
opinion is given as of the date hereof. We have no responsibility to notify you of changes of law or facts affecting the opinions
expressed herein that occur or come to our attention after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
hereby consent to the filing of this opinion as an exhibit to the Registration Statement and further consent to the reference
to our name under the caption &ldquo;Legal Matters&rdquo; in the Prospectus. In giving such consent, we do not thereby admit that
we are in the category of persons whose consent is required under Section 7 of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WENGER &amp; VIELI
    AG</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/
    <FONT STYLE="font-size: 10pt">Dr. Andreas H&uuml;nerwadel</FONT></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/
    <FONT STYLE="font-size: 10pt">Pascal Honold</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Andreas H&uuml;nerwadel</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pascal Honold</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  U .D# 2(  A$! Q$!_\0
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M^R3[%:7M^MO;7%YY;_9H97GV-LP?S$_X)>?'+_@HY\;-!^-=U_P4'_9^\.?
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MX1UWX.^-O,QY<<\]MI'_  K;7I%+%I+@I,[>;AJ^#[?]EOQ#^T9_P1F_;?\
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MZU=VES8VY80ZK;ZI'<PW:P7]E]CN;>)U\CA_BG+,FX;C3J556Q^&\0LIS^&
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MKQ5#-'FZQ&44HX>566&Q^&P=7'TG0G",H)8:.7RK4JDI\M24>=R_$S_@G_\
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MQ:/-=GQ;XT\/^#TE74)[._BA%@^O+J#HUJYN([5K=6B>594^ _%?B_\ :5\
M_LK^$?A_XMUSQYX"\6_$_P#:W\,?L^^"_B-XHUGP_J7Q>T;X"_$#X@,?#OBC
M7=9T34M?TVW^)<'@5+KPFNK7%Y=ZI!JL=KKET\FK,MU)UG[;WP?\+_"3]AKX
MN>&_">K>/KK3M5\6?!NZED\8_$7QKX_U*SNW^+OPXL9[G2=6\;:WKVHZ6]QY
M0OI(;.XBLQJ;27T=JDLC[IC3BIP4Y)J56,+)-IQYHJ3;YE9^\ERIMW4O>T3=
M2J2E";C%IQI.=VTFI.,I123B[_"[MI*UO=UT_4.N)\'?$?P5X_N_&EEX.U^V
MUVY^'GC"_P# 'C)+6&[C70_&6EV.FZEJ.@3R7-O!'/=V5EJ^FS7#V3W-LANE
MB\\SQS1Q_$$.CZE\$?VW_@I\/_!OCCXDZAX$^-'P@^->K^.O"OCOXA^+OB+I
MT_B?X?7O@.YT+Q7HTOC75M<O_#^M31^(-2L]672+RTTS4;62%9-.66WBE7S/
M]D?X9:EI$'_!0VZ^%6M>(++XEP?M _&[P%\/[[Q5XV\7>(O#]EJX\"^"]0\+
M:OK.DZ[JVJ:;J.KVWB.ZMWO_ !7J%C>^([K2XUTRYU"XTZ%+0ITHJ+ESWO&G
M*+M:W/4E!J:NVFN1O1O2S\D*M>:ARV?/5A+7FUITX5/=:M>ZFMTM;KS?ZPT5
M^;G[%'B7P-X;@\1^#?&]Y\<? _[1?A+X<Z!K_P >?"/Q[^(7C#Q1'J)MVNHM
M9^+OA*\UGQ%KO@+5/"FK:[#JD*^)_ ,FGV%M:1VFEZGIFE/!;6B^ /XUCT;Q
MM^RG\8/@+9_M':=\/_BM^T/X2^'NK_$OXL?%KQ#XA\+?&_P/\0--\5*UQ;_"
M[QIXS\1:U;Z?=M8VGB'P1XM/A7P/+:6]E!+8V\NE:A"DJ]E[TE=V7PR<=):2
MDMI.RDHMQ:YNG,HZVKVJM%V3;>J4M8^]&+WBKM.2YD^6VJ3EI?\ :*BORPA\
M#CXW_M#_ +>MCXX\<_%N*#X2/\*K#X61>$OBY\0_ ]IX .M?!FV\3:C?:!I/
MA/Q%I&C2:A/K_P#Q-)+C6=.U59)\Q2QO:O+!)R_@SXM_%75O@-_P3*_:6\1^
M-=;NI=5\6^"_ 'QM2*^FT_1?%^D_&O0=0^'>F>)/%>EVDEOH]W=Z1X_7P=J4
M-[<VH6PO=2O[BS%LMS*M-T;6]]7M%M<K23E2=6*3N[W2Y;V5I=''4E5KW?([
M7DEJFWR552DVK:6;YMW>/9Z'Z[UR'B7QQH?A/5/".CZK%KLM[XVUB]T/0QH_
MAGQ!K]N+[3]"U3Q'<'5[S1=-O[3P_9_V;H]Z(=0UN:PLKF^^S:9;SRZA>6MM
M+^.^F_M-?$_P3)^UE\3=9\3Z[K.@_'7X2_$KXJ?LOZ+?:A=/9^&;[X8?$.^^
M 7AGP_X7M9Y#!:-XT_X2#X5>/)[?3D!NI]=N+TJTOG2'Z>\<:)X0T;3_ (%?
MLY^)YOVA_C;\:=$^#EK=7?A/X<?&#QIX,?4M/TN/1]#UOXK_ !4\7V_C[P/I
MBI<>*;:>UT'4O$>O:EJ=WJ=U?P:%HM])%=/;#HN+7-JNO*G=)04Y/5JW(VHR
MUWO:^B9[923Y='TYFK7<W&.R?QI.4=-K7MNO=?BO^U+X=^'?P-\)_'?1O#&O
M>*O#WC'Q;\+O#6EZ3J=MJ?@+78K?XG>-M$\&6NIZCI7BC18M8TN72)-974;G
M2=2TJSO9X[=K?-N\J2CVVY^(_@FT^(FE_">XU^U3XAZUX3U7QUIWA<17;WMQ
MX2T75-/T74]=,J6[64-G;:KJNGV.V>ZCGFGN0((95CF:/\7_ !9XW\<>-O\
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@U_X#"^B25VX-NR26K#DCJ[/77XIVU=W9<]E=N^B/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex5-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #B (X# 2(  A$! Q$!_\0
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M(_\ "NKB?2_#\WBNZ^)6L6EWHW_"<IKB6FI/<7/W]X&_;8^!/C66[>XU37O
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MQ\)>,](_M>7QK>7_ .S%\(-=\0^#?AUI&D:QXMMKOPNNNPW?A'PII6B.]E'
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MTH/]M:***^4/H@HHHH **** "BBB@ HHHH ,?YR:*** "BBB@ HHHH ****
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M&<G6I.*G1;A.I2@N:$8U(TH4FH0C3C&D^:I,HHHKYX]H**** "BBB@ HHHH
M**** /S=C_85UV[\)?#'X,>)O&?@KQ'\"?@M^T':_&#X?:'=>#]<B\8WWA%F
M^*=X_P ._&>K#Q9+H^I2>'[KXAZ?I_ASQ+I6E:5+<Z3X9MYM;TRXU&\N)CZ'
MX _8=^'/A7X6>(?AUJJVL]_=ZA^U#9^#O%?A^WOM'U'P%X*_:3\<_$'Q-=>'
M]#@N-2OX)+OP]H_CHZ0NHWHN3=W=A]OBBM4F%O%]OT5[%3/LVJP]F\7*$'6^
MLM480HJ6(=5UZE>2AI*K6K.53$2<;5W*4:D'3DZ9YE/)\NIRYUAHRDJ7L$ZD
MI5&J"IJC"BG/54Z5)*%&*=Z2C%PESI3/RT3]@SXAQ?"#XD?"]_$OP"U2V^*=
MEX'\-:MHNI?"/Q)#\-?"FG?#OP4_A/0?B+X.\"Z7X]LA9?%R^U%;'Q9K6JQZ
MM8Z:U]HGARQT_P"QW&BC7;WK=:_8(OO%"W_@WQ9\6K[Q-\,->O$\;^*9M5T2
M:3XI^(?BNW[+C?LIZAXCOO%B:PNBOI6L^&S'\0]1MV\.OJ3^/(F47W]BW,UL
M/T>HK1\29NY2FL13A*565?FAAZ,9*LX4H1K1D^=QJ4X48*E.-G%WG/V]1QJ4
MX629;91=&<HJFJ2C*O5<724ISE3:3@I0G*I)SC*Z:M&/LH)PG\1>&?V:OBQX
M<^''[0_D?%K0(?CW\;O!FD^#M*^(VE^$M3T_PQX('@OX<#X=>!==M/#$GB.\
MU.]U:SE?4?&VJG^W;>"77M5.F62Q:7IMM+<>$^+/^"?WCOQ/X>^&6AZ9X\^'
M/@JT\)?!KPI^SOKND:1X1\2ZOI"?#'P'\5/AY\3?"NJ>%)-0\3VFHP^,D/@$
M:'K#:]/J>E:BNL/J@6&YL&AU#]4Z*FEQ!F="I.K2JT(SG555R^J4&DUA88.$
M(Q^"-*GAZ5.-*ERRC3E!5(-2E/VE5,FP%:$:=2G5E",'32^L5E=/$3Q,I2E?
MF=2=:I-U*EU*<9.$DXJ"A^9_[+_P0^*OPY_:%:VO]!OXO@G\)?AA\;? /@?Q
M?XEL;#1O%/B74OBU\>?#GQ0AMI;6P\7^*(_$5IH^F:#=0R^,38^%WU<3Z;<W
MFDIJMYJ5EI/Z8445QYCF%7,L0L16A3A-4:5%^S32FZ?M)2JSN]:M:I5JU:LD
MH1<Y^Y"$4D=."P=/ T70I2G*#JU*BYVGRJ?(HTXV6E.E"G3ITTW*7+&\IR;N
MBBBBN$ZPHHHH **** "BBB@ HHHH ^/OV1/'_P 5?B#%\?S\4/&&C^*W^'G[
M0_Q#^$7A=M'\'6WA$0:%X"ELHHK_ %%8-7U7^T=4U8:I&]W(IL[6 VBBUM8Q
M-(!U7B']J?X<^$OC%XL^$GB==;T-?!7PENOBYXB\:ZCX<\76_A+3M$TV;4Y=
M6CN-?D\,KX:2WT_2-,DU)M47Q#);7%R9-$@C;5[>2V/L/@KP!X)\ ?\ "61^
M"]&MM&/C+QKKWQ!\6+;W=Y=-JGC/Q0UO+KNMW O;JZ:VN-1:UMV>VMOL]E$(
ME%M:PJ6!Z"^T'0M2>\EU+1=(OY-0TM]$OY+[3K.Z>^T62225](O'GAD:YTMY
M9I9'L)B]HTDLCF(M(Q/IU\3@*V-Q-:6#FL-6I0A1HT)4L(Z%14<!"550A"K2
ME[U''35-VA.6)ISF_=E%<%&AC*>$H4EB8.O3G.56K54\0JL'4QDHTW*4J=1>
M[4PL7-7E&-"<8K6,C\J-8_;$_:*G_9>_:7^-GAX?!ZQ\2_"+X]S^'],T?4K#
M5O$-MH_PIOM-^%>N:'H&IKX?\3Q0ZA\38M(\>M;ZYJ4NHV>B:=K9G1-'N[;3
ME@N_JS]JWXOZY\/=5^!'@GP_=:GI4OQ/^(/BBY\0ZSI$4+:G%X(^#?PK\<?&
MWQ/X?TB6?=';ZOXY3P'8>"XYQ%+/:Z/KFMWUH(KRSM[B'TZ3]F?X#MX,^(_P
M]B^&7ARQ\%?%SQ&/%OQ%\.Z3'>:-I_B?Q$+7P]9C4[E=)N[*2SE^S>%/#\9A
MTN2QMC_9RN8-]Q=M/:^-G@7P?XNTKP9KOBCQ%#X,OOAK\1?"GCGP?XQEFM(1
MI'B0W$WA-M)<7TL5K>V7CS0?%&M_#O4=)D?S-3LO%DMM8A=5;3Y8O1>.R>KC
M,-*EEWLJ4<5C9\BHPYG3KY9A:&#IS5*IB'6^K9A2KUU%0D^2MSI5*CG3CQ?5
M,RIX>NIXWGJ2P^%C=U9<JJ4L?B*V)G%U(453]O@JE&BY.:]^EROD@H3E^>>@
M_M6_&Y+[X2>)_%NN>']1M-4OOV)/%VN:+X7TAM'T>\\#?M[Z[XL^%T?@F:TN
M-1UFYU#5_@_X]T3P]XL\-^*[>\L]1UOPR-7L-1TV5KR>5]G5?VJOC=X-\(?'
M&#QAK LOC7X8\<^ !I/P@N_A+';^(]%^%'Q(^-/B7P)X3\1?"2#3O%NI6O[0
MGBGQ9X4T+45\&:';ZOI%Q?\ CKP_=:/JVFV#7":9+]/1?LL_L^>%O%GPQTW0
MH-/\)Q:5XT3XDZ3X%;6+N^F\:^(_AMX>N=%\"003>(=5U#5H_"'P9M/$%YK'
MA3P%X=:U\+^&=2?2-0L=,T^WTHPW/977[*OP$O8_%QU+PC=ZIJ7B_4O">LZ[
MXEU?QOXZU7QG:7O@'5=0\0>!)?#_ (VU+Q/=>+/!L'@K6-6U;5?"EIX5UG1+
M+0;S5=5N=.@@DU*_:X[:F9</.=.3RR7LI<M11C@J5.3C#,/:0IVE4=+V4J*K
M0KNC*=6I:A2IUXN%:E/EA@<YY*D5CH^T5X7EB:DXJ4\&X3J74%/VBJ^RG152
M,:<4ZM2=)J5*I'Q^T^.WQD\1?L@^!?BUX:T[2=4^('B77?#.A^+-3\.^$]9\
M4GP)X9N_B:O@SQQXUO?ACI=_<:]=>-/AWX8BO]5\9_#.UU#4+GPMXTTO7O#U
MS)JMIX?NH[OQ3X<?M8_%OQC>_L]>,?$_B>R\._ _QKXD\0_#FX^*/A[X17FK
M>$?BQ\0+7]H/Q9\'?AS;7%YJ'BC_ (2#X/Z=\7-&T'PSJ?ARZO?#^K:1_P )
M/XZL]$&N0B.PCO?T'T_X-_#?1OAC+\'M(T!]'^'<MEJEE<Z-I>N>(-.NKF'7
M-2N]9\07-WXDM-6A\3W.I^(-6U#4=4\0ZU<:U)K&N:AJ6I7NJW]W<W]W+-CZ
MM\ /@[J^I?#O4-1\)6YM_A:^@2_#WPS;ZSKVG> _#M[X4D>;PGJ-G\.K#5K7
MP)<ZMX5FD-QX9U2\\.W6H:#<QVESI=Q:W%A82VW#3S')HK%PGEJ:K8O'5*%5
M4:3K4<)7H5XT*48SG.FJU*K.A&E?GP^'I0JU90JXF=*I1ZYX+,V\/...M*GA
ML)"M3=2HJ57$TJM)U:DG&$)NE.G&M*I;EK5JDJ<(RIT(U(5/EG]C[]IWXE_&
MWXF?%/PIX[;PO'IF@Z?<ZUX:_LW2+G1;?5[6'XB>,?"4>L?"K6Y]4U"/XP_"
M5]%T707N/B9;6VD+:^-+V_T.2S$<]K:Z;X?J/[6?[0/@[PMXSTSQMK;6/QVB
M\9?#KSO@Q)\%EB\9>'?AAX_^(7B_P[:>(?@AIFF^,-8M?VB_$-QI>@36NFZ=
M;ZOI\UM<>'=>UG6M'MHTM]&N?T1^&G[._P &/A#KFJ^(?ASX+M?#^KZCISZ"
M95U;7=5@T/P]+J]SXDD\*>$]/UG5=1L/!'A677-0N-:D\+>$K71-">^EBN3I
MY-M9^1REQ^R1^SW=SZY?W_A'4-3\0ZMJ?AO6;GQEJWQ!^(6K>/M'N_!EQK5W
MX3_X1KQ]J7BRZ\9>#;'PW+XC\0MI.F>%];T;2[5->UQ/LC1ZQJ2W6\<QX?6/
MQ-7^S6L%4IX!T:/U6@ZD:V'4E63YJ\X4\/7<HSKJF_K%6<(*C-0AR8G%X'./
MJE"G]>3Q4)XM5:KKU%"5*LTZ35J493K4E%QHN:]C3C*?M8.4^:AY-IWQG^/'
MCK]CCPU\4/ FFV>I?%W6=>TG2=73PSX4M]>U3P]H%C\6AX5\::C??#;5_%6D
M);_$KPOX%L=4N/%_PTN/%+R^%OB'::SX5CN=4;1TBN_#]*_;3\;ZG\3?@!X?
M\)>,]!\>_#SQOI7PH3Q!XYN?AKJ'AG3FU?QS\0/'7@CQ7IGQ;NY]<@D^ /C2
M*Y\,6N@?!?P7J&F:O/\ $GXE6OB/P7=S6TUO%)9_H-:_ _X:Z5\.(OA7HFE:
MMX8\%6]Y>ZJ(/"_C+QGX8UUM5U/6;SQ'K.LW7C/0_$%AXQO-8US7=0U#5_$&
MKWVOW&H:[J%_>W>L7-[-=3O)P^G?LC_LWZ7?^#-0T?X9Z1IC>!['P?9^'M/T
MO5O$-CH-Q%\.M7OO$'@.]\1^&[368M \;ZKX+\1:OJ/B'PWKGC+3=?U?1O$&
MH7&N65]#JLOVNLZ&89%%8WVV7RE&IB<QJ811P]!NE1Q-%QP\:TI5KWPU10>'
MA2FJ=*/M95U5<X3HW5P>;2^J^RQL8RA1P4,2Y5JO[RI0JJ5:5*,:5DJ\')5I
M5(N<VJ:I.FHRC4^DZ***^9/>"BBB@ HHHH ^!/\ @G+\/O$7@?X +>>*O"?A
MOPOK7BCQC\0=5E>T\+ZMX=\=:M9#XE^.7TZ[^)5QK3F\UO73:W*2Z=?B*WMO
M[)N8!:Q>0\;MZ3XLO/VJM'^-?C?7?#'AWP;XN^#^G?!6[N/!OA1=<NM(\1^(
MOBE:3:Q=:9I,ESJ9MM"TR[U2]&GV%[J=Y>Q:5:Z!+#.)!?Q3I7UE17J5\TGB
M,PQV/JX7"U)8YU>:C6C4JTZ4:DZ$E[*3JPJ0J0A05*-524HPJ5>2%-RBJ?!1
MP$:.#PN#IUZ\%A%34:M*4*<ZCIQJQO4C[.4)1E*JZDJ;BXN4*?-*24G/\(M=
M^%/CS5OV*OVX=&\2>"OC:OQ L_VGYO'>AQ:GJ&MVOB/QCXHU+2?@1K&L>)=&
MTOX=^*]6LM?\)CQ'-XB?1?#\<^K>%=*LK!-/BLI/[&E\C[R_;-3Q:_B[]DQ-
M*FMH/"\GQN\3P:E-?(&TN#XDW'P)^+,/[/\ <ZTSJ\*:?#\8W\,'36NE^R_\
M)HWA#.;H6BM]UX[^G]:S-7T31]?L)-*US2[#6--EGLKF2PU.UAOK1KG3;VVU
M+3KDP7*21_:-/U&SM+^QG"B6TO;6WNK=XYX(Y%[I\0U*V)HUZN%IJ-+$X[$>
MSC-S4?KV687+9QIJI",8^R^J0Q%.^G-*5*T(1A,XXY-"G0JTJ>(GS5*&$HN;
MBHMK"9AB,?%S<)2;]I]8E0G;7DC&=Y2<D?@_X"T;Q#I"?!4>%/#/CCPQXB'Q
M,_X)UZ+#:>(=#\1Z#J-]^T-X?F^)<?[<NK26NN6=I=ZG?2? "?5+#XJ>+K.*
M[TOQ#?6TDS:MJ%_;2SG8U_P[JGAOP/\ M'> O '@V/Q9X3;XG?!?QI>?M%0?
M WQMH3:EXI\5_M"^-_&'CWPC^T!X,E,>N_M!?#WX/:3;:)J'C9/!S:;::YX$
M\9Q>%+Q_#DT%[XAL_P!Q[G1-'O=4TO6[S2M/NM8T2+4(=&U2XLX)M0TF+5DM
MXM433KN2-I[(:A%:VT5Y]F>,W,4*1RED&VM2NV?%<I5(U/J,9>]&I.$\1/E=
M6&-CBJ<G.-.-2JJ*4XTH56Z7-6G*K1FJ=&5+FCP\HPE#ZW)73A&4:,;JG+"R
MP\XJ$IRA3=5N,JDJ=JEJ4%3JP<ZJJ?F+H7@76_%/_!/7P+HNO'Q!X4F\*:KH
MWB?6]"\5^&O&^OV'Q#\/^ /C)-K;^&+GP)HND2_$2'X3_&#1=*@'@_P$N@7W
MB+PW\._$?AGPOK.A:TVE:CI5_P"">"/AWXT^'&O_ +(7BCQ5\.=(\0_%J[\1
M2:!9_L]:UX#\5>/%^!GP?^)O[1OBWQQ;^*/!'Q@"KH?@+6_V??AMK.C6&I6F
MOPS0W?A_P):^"M+&FZC>^'Y9?VUHP.E<=/B.M36+A]6INCB\7CL5.FJLXN*Q
MM&M2GAU4A&%3V3G652I-.&(G&C2P].K1PSK4:W3/)*<WAY^WJ*IA\-A,/&?)
M"2;PM6E.-9PDY0]IRTW"$&I48NK4K3IU*ZIU*7Y$?\$]=/\ &>G?&7XP3>(?
M"_C73+/6/#%]?W$FM^'?$WAV^\(ZPWQA\?ZK%X%^-.M^(((--^,/QM72_$,=
M]8_$WP>/[%B\ 6-AX?D@DMXM%\2>*_%M*^&<-EI?Q+\%>$_"6D_$3X;_  W\
M2_#GXM:]\2'^ /Q*\+ZC^TGXTO\ QU\48/$'[,WQ:T*WM=5\0_%G5M-E\1^'
M?'.D>+?#NE7OAK2M=G\.6?C#PXNGQ732_O!16LN)ZKQF*Q<<)"'UFG@8.C'$
M5%3A+!)PC6YE3A4E4]E.M3IW:ITW5=>5.6)IT*N'SCD,%AL/AGB92]A/%2]J
MZ,'.4<4U*5+E<YPC#VD*4YV3G-4U14U0G5IUOS:D^$&M6'_!/[X9?#']H7Q1
M'X4UO0K?X9:SXRBU#PUKOQPT/39?#OQ TKQWI7PJ\2:-I5Q'JWCOPCI5K8:9
M\.-8NA?VPU72-/>Z>^59P[?,?ASX:?%_QQXI_9;\::9\*M+\ >,?%3? K5+O
MPK8>'/''@NQ_99^''P6^)_C#6OB!KW@.6336\/\ ASPS^T;X)NH/#^I_!OQ-
M?Z9X]>7Q;:V.O0>(K/P[J$WAK]P<9_\ UD?RHP.??K_*LJ'$>(H1Q-L/1G4Q
M.*Q^*:;E&A2>84ZL*U.GAX<JY'.=.<O:3G.<<-1H<\:%3&TL7I5R2C5=!.O5
MC"AA\)AU;EE5J+!SIRIU*E:5WS\D:D%R1A%.O5J\KJPPM3#E%%%?.'MA1110
M 4444 >01?M!_ 2;4QHL/QM^$DNL'Q GA,:5'\1_![ZB?%$ERUE'X<%DNL&X
M.N27RM8II0C^W-?*UFL!N5,0UI?B[\.WN]5TW2/%>B>*-7\/>*_#7@SQ1HGA
M35M*\0:UX3UWQ7KMOX=TN#Q1IFGWLMWH*)J,["\.I16\EO#:7SB*1[26-?RT
M;_@FU\1V\!>,?#+>(?A6=7\1?LV77P:M-0$.N(L/B63]J'QM\=+?5)[Q?#QO
M8M'@T'Q+9:>D\"R:C#XCAN9H;1;98;V3T.Z_8L^.GB;XJ:Q\1?&WC7P1K.HM
MXV^"=_#KDVM>*+JYU_PG\)OVU]&_:5L(%\*GPY:Z!X"FT+X<Z3;^ M$T70[G
M6H=7\51S>(-;UZ)+RXO)/JYY5PZG-T\^YHPA+2I3@I5*BLX<BIT4_9RM*,O>
M]I"3I2M.FZKC\[#,<[:2GD_+*4HVY)R:A%W4N9SJ/WX^[):<DESQO&:I\WV'
M\.?VFO!7Q)^$WPX^*ND:+XL4?%'1[S6_#'@>#2H]7\:36>G7[Z??RW%CI%S=
MZ?:VMG.(%N=3NM2M]*BFOM/LFO1?W]G:S^@:;\9OA?J&G3:A-XV\/:&UD+4:
MOIGBG5+/PQKF@37OB63P9:6VOZ-KDUCJ&D3W?B^&7PO8_;8(HM2UQ5T_3);R
M:: 2_FL_[(OQ1\!?"7X4_#G4GT;Q*OAGX/ZA\.M8U+0_#.L^._#EKXDN9/BF
MMCKI\+)>>'M?OFT>?Q]HGB+P_+):-IZZUX:EEU&;0]1M/#6KQ;?CW]A'Q1\:
M-/\ AI=ZK>:-X3M9]#^(6C_&;0-8-W/J/B.U@3P]XE_9_319-/FU=;>W^&'Q
M1\">"/%JQ:UJEQJ<UI::C/=3#7-1N[6-U,LX?=:;_M1T,)/%8M4JT&L1*&'I
MU,1*A#V<XQG/FHTJ<(3E&$Y5JM+VG)3J-TW#'9PJ,+X#VN)CA\,ZM*?[E2K3
MA1567/!RC!1JSG*4(RE%4H5.1RG!*?Z0W/Q2^&5GJNCZ%=_$3P-:ZWXBUK5?
M#>@:/<>+=!AU37/$6A7?V#6]!TBPDOUNM2UG1K\BQU73+.*:]T^](M+N&&X(
MC-73OC!\)M8/BT:3\4/AYJ9\ +<-XZ_L_P :>'+S_A"TLY;N"[?Q6;?4I!X>
MCM9]/O[>YDU;[(D%Q87L$K)+:7"1_GEX1_80\>Z1XA^%.N>/=;\-_$U;GP!\
M.=/^/-C;^-O&7P[LKCXP>%_CGXQ_:)\2_%3PD-%\-:MJ'BS3];^)/CW5-1@\
M'Z[J7@R-Y/"_@^35-4NXC>V]IYUK/[!WQ$\'>$K37KS7?!>HR>"O!OCB:^TK
MP_X:\:>)I?&NM7/[>GA7]KSPWX;U+P[X=\,7>NZOX4USPUX>N? GBZ/3]-U;
M5;"ZU_5+G2=#UO3Q<+>Q#*<@E+V:SZ3FU",)1H4_9SJ.O5IRC'F2J*+C2CR.
MI&DFL3AL0VZ*KTJ3EF.<1CS_ -D)17,Y1=:?/""I4YQ<FFX-WJ2<E!S:="O1
M253V4ZGZHV7QB^$FI/X/CT_XH_#N^D^(7VP> H[3QIX;N)/&QT^>2VOQX3CB
MU)W\1-8W,4MM>+I"W9M;B*2"<1RHR"*P^-'P>U3^W!IGQ7^&VH?\(RMP_B/[
M#XY\,77]@I::H=#NI-9\C5)/[,CMM;#:+</>>2D.KJ^F2E;U&@'YB?L_?LC_
M !,U_6?#GQ@^(7A*#2M$^(/B:3Q9XJ^$/B'Q]XN\#ZM\-[[P9^U[\</VA/AK
MXFTVTT7P7+=^+GU"V^(GA_7K[P3XFF^'4EGX@T6Q7Q%!(UWJFDZ7V'A[_@GY
MXPTS0OV3-+NO$_@&&7X3^)_'-C\>8['3M2FM?B;\)]9^+Z?M ^&/"NB--IUJ
M3?Z=\5O!WPXN-0&M6\%C_P (_>_$"SMY)I=4A%V5LIR&C4J4IYW/GAS1;A3P
M]2$:D(8NI4I\U/G4W&>&A@XS@_93Q&)P]>G.>$J3= IYCF]6$*D<JCRSLUS3
MK0DX2GAZ<)\L^3E4HUY8IQDN>%&A6I3C'$0BJOZ%Z7\7_AWJ-UX?TFY\5:+X
M>\2>++WQ'8>&/"/B?5M*T/Q=K\WA;6=3T/5WT;PY>7RZGJD,-WI-W,DEC!<9
MLPEQ(L8+*G(_ +]H+PK^T'X'T;QUX;TCQ#H-AK/A;1?%J6GB*VLX9+;3M=U/
MQ/I=G%)=V-[>V4MY%)X5OYK^&&=TLX9[%FD8SD)\-?"/]@?QS\/_ (CVOB7Q
M?J/A;Q_X6UKQIIWC36=#M?'WC/P;!X+\0>"?VD_C;\=_ 7B'1=-TSP?=CQZV
M/BAHMSJGAK6M9\(Z/:^+]#U*::?Q'H^LRK%)\)/V&/C%\._AC\4OAM=^,/A\
MW_"XOV=?AM^SSK_B71KWQ/!J?A6Q\.Z;^T=9^(_&/AR*30(1J>JVMS\7?"MS
MX8TR]N=+@N/[/U_[=J&EO#IQOG6RWAZ-*O&CG$:E9SP<J5:2G&G&G.K&&*A"
ME&'/4=&G*I4?MO9SG+#PC1<XXJ+I*GCLZE4I2J99*%+EQ*J4HRBYN<(.6'E*
MHY<L%5G&%->RYXP5:4JO++#R53["NOVMO@=;_$OX??#I/'WA&YMOB9X+\=>+
MO"GCVW\9>$9/ NIW?@+QG\/_  1J/@ZRUL:ULU'Q;?:O\0]-&GZ5IR73,EC?
MQ3/%=_9(+CZ8K\K_ (K?L5_&#XO^ ;#1=1/P6\&Z_8_L;?%G]FB+3/#]YXEO
M_"-MXH\6>,_@9KGA?Q5I+2^#=+O--\/IIOPKU9[_ $]-/EU/0[N^T6RL)M:C
MM[G48OU0KS,RPV64*6$E@,4ZU5JK3Q=-SA5494ZE9TZ\:D*=*%JU-T8N$$Z:
ME'FIM*4HKOP%;'U:F)6,PZI4TZ<\/4490YHSA24Z+A*<Y7I3]K)3DU-Q?+--
MQBV4445Y!Z04444 %%%% 'Y]>!?^"AOP[\?>(/#/A'3? ?CBR\4>*-+^!$ME
MI5ZVAA%\3_%W5M8T_P :^"?MD&H31S^(/@#9Z3%K/Q42W5[>VT_5=,;1Y=0D
MN-BU/#'_  45^'WB[5=(\,Z/\//';>+]=\/?">[TOP_=S>'[47/CCXB_$/5/
M 'B;X8#4FU)K0>*_A"+"T\5?$,Y.GV7AG6--O+*XNY)7A7W3PQ^Q[\ O!_CC
MPS\1/#_@Z:R\5^$/B)\:_BKH-\=>UR:WL_&O[02Q)\3M1.GS7[V4UMJL<,46
MEZ9- ^G^'8HHX]"MK%5&$T#]CSX ^&/'&@?$71O!LUMXK\,_%GXL_&W1[U]>
MUR>WM?B+\;=$'A_XAZN=.GOY+&6UU/35C6PTB6!]+T.ZA@O='M+.ZACE7Z>=
M?A.]7V>!S-+ZNW14J[?^U7K^Y4_>_P"[VCADY7]I^\K65X0<O C2XBM3Y\5@
M6_;)5>6DM</:E>4/<_C-NNU&W)[M+7WY\OC/PZ_X*&?#CXF^)_"_A'P_X'\;
M+K7BZV^ DFC0W3:&L-U>?&/1-?\ $?BW2X)8M1D,]_\  ?1] ,_Q5BC4K8SZ
MGI=IIK7LMR?+9K'_  4-^'NB^)]2\%77@'QQ)XLTVW^+MC)I-O)H4D<GCKX;
M?%ZR^$_ACX<K>G45@'BKXO+<7/CGP!"P^S3>$--U"[U&:TNHA;-ZCI_[$7[/
M6BW^D:QX<\-Z[X7USP]JGQ\UOP]KWAOQGXIT;6] UC]I;4H-4^*NI:/J5GJD
M=Q87=[<6\4/AN6!E/@VR5K'PP-,M7:([.K?L>_ '6_'.I_$;4/!LTGBW5_C3
M\._V@K_4(M>URWBF^*7PL\'_ /"#>#-=%E!?QV<=K8Z"9/MFC1PKI.K:I-/K
M.IV=UJ<TETPZW"7MI..#S/V#H/D@ZK]HL2JLVN::J\KH2H^R3LO:*I[1_#[-
M@J7$7LHIXG ^V]JN::IKD=!TX)J,73NJL:GM&F[P</9KXN<\"O?^"CWP\2S^
M(VI:-X"\5^)M,\(BZB\+7^A:QX5NX/%]YI_QT\/_ +.UY8ZP_P#:FSX;WD_Q
M$\2Z=>:%9>,'M]0U[P1#JWBBRL@^D7VE16+C_@H7X=2QO_L?PE\::AX@\#W.
MNQ?&;P_#K7A6'_A6</A_XZ:M^SW-+#JEQJ$=IXREUGQWX<\37?AF#11"-1\-
MZ!?ZAJ$NCW\EAI5Y[E/^R)\'Y]#\9^$"/&L?@+QKXFT[QC=_#R+QSXB3P3H/
MB:Q^)5C\7I]6\(:$+PQ>&9-7^(=BOB+5K739(M/GEN]0M+>TM=/OKBU?PWXQ
M_L#:#XWODC^'&OK\,;+Q1XJ\0^(OBCXCMK[Q?J'C#Q%9>*?C1#\=/$/AVU@3
MQ':^%K[1=1\9S:[-I=IXCTC4D\(-X@U"3P_LLKF_TC4-\//A"I45.I0Q=&/-
M%JM6JXEP5.-*DIJM&E-S<Y6KM1P\;2Q7L)PFL-*I0CE6CQ)"#G"KAJK46G2I
MTZ*FYN=3E=)SBHJ*O1O*M+W:'MHRBZZA5=1?^"C_ (!O]-\<:IX<^'GBOQ/:
M:)=>'K3P1=:/K/A::R\;3^)/CUH7[.=A;ZO?_P!I&U^&]]+X]\1Z7JMMI'C"
M2WUF]\!O=>)K:P>YTW4M'M-+Q-^WEH>GV6KZ3'X1U[PUXT\+>+M:\)^.;'4;
M'3O%<'@F[T/X\_";X+:4U_9V'B7PV^IV?Q._X6KIGB3P-J-KJ=MY'ANWU+7=
M2L9KC27\/7WMZ?LD?"*/1/$?A)!XS'@7Q#XT\-_$"+P!_P )OX@/@SPOXI\,
M?%'3_C-:7W@W1#=F+PU;WOQ%TZ'7=2TVPD739XY+C28+2VT>8V L>(OV2_@?
MXG\0_%[Q5JGAF]_M[XYZE\'=6^(VH6FOZS:2:K?? ?5]-USX;S6445X(-&_L
MW4-(TZ75%TJ*U7Q MI#'K0O4C0+@J_"JJ?[CC_9IQE%^UJ3F[/"P4:L9U53?
M[J6,JU%!.+Q-*C&G)8>O*%#5T>(7#_>\)SM.,E[.$8IN.(DY0E&#FOWD<-"G
MS-25"I5<TZU%2J_)NL?M^Q_$?2K.+X.Z??Z$\WQA_9FL-(\87A\/>)]$\5_#
M#XD?M6^#/@?XO@NDLGU)/!/BO5-*U'4KC3?#7B%;?Q1;>'M7T[Q-:P07MGJ5
MGI7N/AG]KFWUWX2?L[^,-%\+ZIX^\;?M'Z_J?A[P%X6TZVTSP MY+H.E>,?%
M?B35=6;7_$_B&Q\.:5H'A#P3K-],C:]KE]J=^NGZ?I]N\^J*EIWVE_LG?"72
M-)N/#-FOC'_A#%^(/@GXG:#X&F\::_/X0\%^*O /Q*M/BWH4G@K1I+HQ>'=*
M;QW90:I>Z':2'2IK-1H<5K;Z&D6G1Y5C^QQ\'=)\+>#/".B2_$'1--^&U]H>
MJ?#:ZTKXC^+;35?A]J>C6?BW2I[_ ,)7PU)FTN?Q-HGCGQ/H/C--DMOXLTC4
M([76H;HZ?ITEJZV)X8G"G3HX7%4HTL14J1E.$JDZE&>&E&$*]2-:%63ABO85
M*M.G)0]G3Q,<-.*Q%-4BE0SZ,YSJ8C#U'4H4X.,91A&G5A7BYRHP=.=-*6']
MM"G.HG)SG0E7A)T)^T\A_9R_:R\6^+/B%<_"GXH^'+YM0\7_ !C_ &R?#WPM
M\=Z?-X=.D:AX?_9V^-6K>%?^$7UG0],-OJ6C7VB^$[S0K2RUF[AO1XEGTO4K
MR]GM;FXM#??H37@/AG]F;X2>$?%/A7QGHND:I#X@\&>)_CCXPT*[G\0:O=1P
MZ[^T5XB3Q3\4[FYMY[IX;R/6-:1+FPM[A'AT5!Y&F+;PDH??J\G-*V7U\3&K
MEU">'I2HQ5:G*+A#V\9<KG2@ZE3DC.E"$I1C+E5651QC%2:7H9?2QE&A*GC:
ML:TU4?LIJ7-+V37,HU)<D.:49RE&,FN9TU!2;<;LHHHKS3O"BBB@ HHHH **
M_"WP_P"/?%LOACX":CHGBG5M;_:VU/\ ;OAT3]I7P/XD^)GC?15TXQ']H^#1
M_"'B/0K7_A)K;P9\+K70]/TA? *:/X/_ .$=\2^'M(\+:I&NJ&Y&KG-_9S\8
M>,=<_:T^']A\6-9TV6Z%E^U9>:;H/C'XX^/-%TO3_&NE?M^_&W0M&M/AOID^
MEV]A\4M2T_0++1/#FDZ;K>FZ(;+P79Z2+"SBT_RM-/ULN%*L*6+K/&TK82AB
MZTH*C-5:OU2?LW*C3=1N6&KO][AL5K3K8=QK1BN96^<CQ%3E4PU)82JGB:N&
MIJ;J1]G3^LP]HHU9*%HUZ2O3KX=6G2K*5.4O==_WDHK\D/VN-6_:(TCQG\&?
M%FD7?BOPE\4]9^#?[:MEI_PS^&OQ#\1^./AS+XL\+_ 3Q+K?PTU2VTZ?PGX+
MAU[Q=)KPTNXTZ;6?#LDMCJ'_ !+=(:022W%S\\>)?' A@\16FD_$KXD)^R5:
MZI\0YOAQXZT_QOX[GN[WXP6G[*7PZ\1^&-!L_&9UB7Q)J<@^*-UX]UG1?#L^
MH7%A>?&FWOO#,=A-KNGV^B19X7A>IBJ&'KQQU"U>/,XTZ52MRRC7KT)TJ<X5
M8QQ%64J/-AXTE%8J"Q#I\OU6IS7B,_AAZU:E+"5KTI**E.I"GS*5*E5C.<90
M<J-.*J<M:4W+V$G14^;V\+?OM17Y7^+TTWXW>,/V-_A[KMUKI_:&$?A+Q+\?
MK_PUXQ\<^'F^'N@_!?PQX(^)OQ%\/:]H_A3Q)I/AZ'4O&'Q$\;?#KP+<VNJV
M%W)=^&/&^O0PL\>GK'!XSKWA7XT2>+_VK]!B\?\ Q';3?"'P/_:=U[XI?&3X
M>?%KQG%:>(_&_B'Q;;>-/V=/ VBZ5=6T,'PQ^(?PE^&EMKWAOQ#IOPXN'6Q\
M.W>@M>:I'<:WHZ094>'XU%&-3,*>'J^R=:<*N'J./LO[2674ZU*<:R]M1Q$K
MU<,TJ=7$1=-TJ,J51UZ>E7.7"[A@YUJ?.J<9TZT;^T^HO&SI58ND_95*,;4Z
M]W.G1DIJ=2-2"HU/VVHK\<_VBOB9X=O/V O!&H+\2]+L/C?X1^#G@6:TEU#X
MK>._ _Q,M_'$OP=\&^,-9'@"U\*W:ZEXY^/+Z1X@T'5_A[X3\16NI:1K7B?6
M](A\0J=*U'4X;K:^*WQ@U1_VJ?AMJ'Q9@^-OPU^!.@_!W]H6PU^UUBP\2^&?
M!VL>$;'X-^!/'WC#XD>,-9\)7T,)\2:9>S7O@SP[!:.FK^&KW0-?DT3R+OQ?
M$H*7#>(JQE)5>7DJ9M3<'0FJE266*#A]5IRJTYXGZZJD515-3Y)-<[:E!3)Y
MY1A**]G?FIY=44E6AR0CCW)2]O-4YQH_57!NJYN',D^1)QDX_KE17Y*^!_%=
MW9?\$YOV@O&GAWXC:KJ]IXWA^+MS\,]/T3X@WOCOQ/\  W0_B4L.A?#SX9Q^
M.;?5]9UP>,?!D&NZ5KNHVTFKW5YX-\3:U=^'=*NGTG0=)F;Y)U;QA\=-2U#Q
M4EQX\^*=AJ7PM_9F^*?P5T:VMM8\6067BKXR_L _$'X._%/Q)\1WABN8QJ^J
M?%R*?5O"TNIL'F\5Z#!J>D327>E37<$VV&X6JXFIC8+'4:2P>-J8*4JM"M&4
MIPIX1\WLW*,HVKXJ>&FO>4)X:M54ZE"5&=3*OQ!3H0PTGA*M1XG#0Q,8PJTF
MHQE/$KEY^5Q;=*A&O#X7*->E3<(58U8P_H@HK^?'P9K_ ,:/BO<?%G1?$'QQ
M\;?!K1[OX*^,/VQ/#7Q/\::]XCTOP9X-T#]M#7O!5Y\)/AMKUZFI:%+8Z!\/
M-'\%_&'P3=06.JZ?KW@2Q\00:OH%WI>M6^FWR^_? #6-*^*?QN_8N\86O@_Q
M%X)L(_AQ^V?HUYI6C_%3XG>,_AEXMU/X,?$WX/\ A7P=\1_".L:]J&F#QWX!
MU^/Q!XQ\0_"_Q#XJ\/6]_>^&/%;@6CPV]K,E8GA:>%IUYU,=3F\/1J5:JHT)
MN,'' U\;1IN=2M3C*5=X;$T+495IX>="4\11ITJN'G65'B"%>5*,,)./MJL*
M=/VE:"<T\72PM6:C"G.48T57H5;U8TXUHU5"C4G4IUXTOV0HHHKY,^B"BBB@
M HHHH ;L0,7"*';;N;:-QV@A<MC)VAF"Y/ )QU-,>""1HWDAB=HG\R)GC1FC
M?KOC+ E'S_$I!]Z(+B"ZB2>VGAN() 3'-!(DT3A6*L4DC9D8!E93M8X8$'D$
M5535M+EU2YT./4M/DUJRL++5+S2$O+=]4M-,U*XOK73M1N=/60W<%A?W6EZG
M;65W+"EO=7&G7T,$DDEI<+&TI7=E*\4W*R=XI63<K*\4KI-NR5TFU=)J\=+M
M:M)7:U;NTEKJW9M)7;LVD[-J_@'!(&1T/IVX]..*:40C:44KN#[2HQO#^8'Q
MC&X2?O W7?\ -G=S4-W=VMA:W%[?7-O965I!+<W=W=S1V]K:VT"-)-<7%Q,R
M1000QJTDLLKK'&BLSL%!-4[G6]%L_P"R/MFKZ7:_V_>1:=H/VG4+2#^V]0FL
M;O4X;'2/-F7^TKR73;"^U"*UL_.GDL;*[NT0P6\TB"C)_#&3O=*T9.[2<FE9
M/513DTM5%.32BG)#<5NXK9ZM+1M13U:T<FHI]6TE=M)Z>!G=@9(P3@9('09Z
MX]J,#!&!@YR,<')).1[DDGU).:6J?]HZ>-0&DF_LQJK6;:B-,^U0?V@=/6=;
M9K\66_[2;-;ETMVNA%Y G98BXD8*1)N]DW9-NR;LENW9.R5U=NR5U=J^K;2W
MLKNRO;5OHK[M]MWV99:.-RA>-&,;!XRR*QC<*5#H2#M8*2H9<':2,X)I61'&
M'56'3#*&&#U&"#UP/RIU%("-(88E*1Q1QH6+%$144L<$L54 %B0"3C)P*DP/
M3IT]JSTU;2Y-4N=#CU+3Y-:L["SU6\T=+RV?5+73-1N+ZTT_4KG3UD-W!87]
MUI>IVUG>2PK;W5QIU]#!(\EI<+'H4VFOB35TI+F35T]5)7M=-*Z>J:5TVE<2
M:>S3LVM&G9K1K1NS3T:T:>Z3$95=61U#*P*LK ,K*PP58'((()!!!!!P: JC
M "@!1A0 !M' P,=!@ 8'' ]*6JUY>V>G6MQ?:A=VUC8VD3SW5Y>3Q6MK;01@
MM)-<7$[I##%&H+/)(ZHH!+,!25VTE=MNR2NVV]$DE=MO9))M[)/8;LM79);M
MV226NK=K)6;WLM7YEFBH;>X@NH(+JUGAN;6YBBN+:YMY$F@N()D62&:":-FC
MEBEC97BDC9DD1E96*D$TK?6M&NY-4BM-6TRZET2_CTK6HK>_M9I-(U26SL=0
MBTW5$CE9M/OY;#5-,OH[.[$-P]GJ-C<K&8;NW>1\LM?=?N_%H_=N^5<VFEY>
MZKVO+W=]!76FJUVU6ME=VUULM7:^FNVIIT444AA16-J7B/P]HRROK&O:-I*P
M-9),VI:I8V*POJ5]::9IR2FZGB$;7^I:A8:?9*Y!NKZ]M+2 23W,,;ZL<L4J
M++%)'+$XRDD;JZ,,D95U)5AD$9!/(--QDDI.,E%[2<9*+M:]FTD[75[-VNNZ
MNDTVTFFUNDTVKWM=)MJ]G:Z5[.U[.WY@_LS?L]?M1?"GQK\.)_$?B&ZLO 6@
M:Q>Z-KW@^Q^(ESJ/A"/P!<_"CQ'<%;+P8(DT4Z_)\;[S3-7DUV"UB\1-I[W,
M3:H=$+Z8WF&M?LT?MK3_ !#^*?CBT\5:QIVH>*M0\%^&_$/BGPO\1UC\6>.?
M!7A[Q?\ M1:YX<N/AI:7VLZ%IGPSTWX?VGQ7^$5Q)X+U#4-+T;Q'J/@WQ3%J
M]EXKM;^<^+;%S^VM^T/JGBGX7VGASP1X;.O>*W^,7@SQ'?MH'Q$UKX3Z)JO@
M?6M(U2QU/P_<:/KT%OX_TRZT:WET'3_&RW_AR6YU>\U.%] T&]TG6?"8]6^!
M'[27Q9^-_P"T_P" [+6])N_A_P"#(_V?/&?B75/AFNF>(OM1U7Q#I/[*OBOP
MKXW\3ZYJ"VVD75A=7'C3XC>$_ 5E:Z78ZA!_PC/C-M2N;C41J&D:!^A5?[?P
M\\9F5:AD2YLOJSQ'[NA4;IX7$2K.'LH-SE.O6:4*E13A+EI5:JC*%!5/BZ?]
MCUHX;!4JN;/EQE*-%<]:"52O15'F=224%"C3UE"#C*/-4A3;4JO)W>O_  (^
M)WB;]G'X[>!_B--XP^(WC;QA\7?%WC'PA!:^/=#:\;0=%^*-GX@^#L.G)XTL
M[[X<:%I.EZ'H'AF^\0?#Z_\ #]QX+U=(M:T37M'UF/6M16^\+U3]FO\ :Q\=
M:'H%A\3KRWNO''A?XM>'OB-I_BSX??$[6O!W@'0M*TW]F3XF^!]$T#X4^$[&
MZLM3\ S^$?BIXCTZ+5I8K2%_%^CZD^HZAJFI:='/X?TS@/#/[<'[5-O\.X=?
MM/AKX6N;;0_"/CS5+BQ\3^&OBKJGBK5K_P"&W[/FD_'S4(VU;^UK?/\ PF5S
MJLWPWT!9M.N;G1=7LAJ<C>*+AF\,1?0/QU_:<^+?@?\ :5^&UGX4\+^-+_X*
M>%O!]O:?&-M.\&IJ?AJX\<?&?2?$;_#"'6/%#P_VUI+^!]>\&>%[&^'ANSO;
M.2S^,*7/B(VPTJT$6=.AG^$KU*$89,YSJ8W&PGST91I5,+A:-*I0HJ$Z<,/]
M;A"G3AATIPQ-::C4G)4^25RK9/B:4*SGF:A&&%PLH\E:+JPKXBI4A6JN49RK
M?5YRG.5:3A+#TXN4(ISYUYSX-^!7_!1RV\16 U_XX1#0CHNLZ4;O4/&$NIRV
M&JV'@&Z\?>#?%.H6%IHJ+JTUY\>_'_B#X=>+=*B?[!<_![X4^"%MX'35);*+
M&O\ X!?MK/X7T6.;7OBAJ^HZKX+TOPIXFFL?C=9^'?'G@N_O?C'X/UOQAK/@
MGQ1#XKDGUR.U\ :1XND\$-XJ\87%RE]XGL]-UBTM=*TJUT&SEF_;X_:9\/\
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&1115@?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
